Trump joined by Joe Rogan as he signs order to speed up psychedelic review

President Trump signed an executive order to accelerate the review of psychedelic drugs like ibogaine for potential medical treatments. The signing event at the Oval Office included podcaster Joe Rogan, a vocal advocate for ibogaine's use in treating conditions like PTSD, particularly among veterans. The order aims to ease restrictions and promote research into psychedelics, which currently face strict federal regulations. Trump expressed optimism about the potential impact of these drugs, suggesting they could significantly improve the lives of those suffering from debilitating conditions. The initiative reflects a growing bipartisan interest in exploring psychedelics for therapeutic purposes.

In April 2026, President Donald Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, derived from a West African shrub, has gained attention from veterans and lawmakers for its potential to treat conditions like PTSD and opioid addiction, despite safety concerns. While these drugs remain in the most restrictive category under federal law, the administration aims to ease restrictions and encourage research into their medical applications, such as severe depression. Trump stated the order would accelerate access to potential treatments, emphasizing the potential for significant impact if the drugs prove effective. The move follows pledges from administration officials to ease access to psychedelics for medical use, reflecting bipartisan support for the issue.

President Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, currently classified as a high-risk, illegal drug by the federal government, has gained recent attention for its potential benefits for combat veterans. The order aims to accelerate access to research and treatments involving these drugs, some of which have already been designated as potential breakthroughs by regulators. Trump stated the directive could offer relief to individuals suffering from debilitating symptoms and potentially improve their lives. The goal is to assess the potential benefits of these drugs and their impact on treatment options.